Is Blueprint Medicines Corporation (BPMC) a Buy, Sell, or Hold?
NASDAQ : BPMC
Blueprint Medicines Corporation
$129.46 USD
$0.18 (0.14%)
- Volume
- 2.98M
- Average Volume
- 3.29M
- Market Capitalization
- $8.36B
- P/E Ratio
- -120.99
- Dividend Yield
- 0.00%
- Price Target
- $120.00
- Year High
- $129.55
- Year Low
- $73.04
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.85
Analyst Consensus Summary
Consensus Rating
N/A
34 Analysts
Rating Score
0/5
Recommendation Strength
Upside/Downside
7.9%
vs Current Price
Price Target
$120.00
Average TargetPrice Target Range
Lowest Target
$41.00
215.8% UPSIDE
Average Target
$120.00
Median Estimate
Highest Target
$155.00
-16.5% DOWNSIDEAnalyst Breakdown
Overall Consensus: Buy | Total Analysts: 34
| Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|
| 1 | 17 | 15 | 1 | 0 |
Analyst Ratings (Detailed)
| Analyst Company | Analyst Name | Price Target | Price When Posted | Date | Upside/Downside |
|---|---|---|---|---|---|
| Guggenheim | Michael Schmidt | $132 | $127.6 | 2025-06-03 11:07 AM | 3.4% |
| Needham | Ami Fadia | $135 | $89.24 | 2024-10-31 03:16 AM | 51.3% |
| UBS | David Dai | $88 | $84.4 | 2024-10-24 12:04 AM | 4.3% |
| Stifel Nicolaus | Bradley Canino | $155 | $90.94 | 2024-09-19 11:58 AM | 70.4% |
| Oppenheimer | Matthew Biegler | $130 | $102.045 | 2024-08-01 10:27 AM | 27.4% |
| Barclays | Peter Lawson | $105 | $112.19 | 2024-07-29 01:43 AM | -6.4% |
| Oppenheimer | Matthew Biegler | $125 | $116.55 | 2024-07-08 04:59 AM | 7.3% |
| Leerink Partners | Andrew Berens | $97 | $107.19 | 2024-05-06 02:03 AM | -9.5% |
| Raymond James | Christopher Raymond | $104 | $106.285 | 2024-05-03 05:57 AM | -2.1% |